Title: 2017 ACVIM Forum Research Abstract Program Document date: 2017_6_15
ID: ri2w5iby_170
Snippet: PAC-1 shows therapeutic promise in the treatment of canine intracranial neoplasia, as well as high grade human astrocytoma. Investigation of therapeutic approaches that combine PAC-1 with radiation therapy and/or temozolomide will further elucidate its therapeutic potential in murine models and canine patients. Canine B-cell lymphoma is a common hematologic malignancy and a clinically heterogeneous disease. Little progress has been made to improv.....
Document: PAC-1 shows therapeutic promise in the treatment of canine intracranial neoplasia, as well as high grade human astrocytoma. Investigation of therapeutic approaches that combine PAC-1 with radiation therapy and/or temozolomide will further elucidate its therapeutic potential in murine models and canine patients. Canine B-cell lymphoma is a common hematologic malignancy and a clinically heterogeneous disease. Little progress has been made to improve remission duration and survival. The primary goal of this study was to correlate modified WHO histopathologic subclassification and flow cytometry (FC) with clinical outcome. We hypothesized that histologically distinct subclassifications would have unique cell surface markers as determined by FC, and these subcategories of disease would have variable outcomes when treated with a standardized treatment protocol.
Search related documents:
Co phrase search for related documents- cell surface and FC flow cytometry: 1, 2, 3
- cell surface and flow cytometry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cell surface and hematologic malignancy: 1
- cell surface and high grade: 1
- cell surface marker and flow cytometry: 1, 2
- clinical outcome and flow cytometry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- clinical outcome and hematologic malignancy: 1, 2, 3, 4
- clinical outcome and high grade: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- common hematologic malignancy and hematologic malignancy: 1, 2, 3
- FC flow cytometry and flow cytometry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- flow cytometry and hematologic malignancy: 1, 2
- flow cytometry and high grade: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date